31st January 2022
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, confirms that, further to the announcement made in connection with the Subscription to raise £1.65 million with Lanstead Capital Investors L.P., at the General Meeting held earlier today all Resolutions were passed by way of a poll, the full results of which are given below.
Download News